Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
Subtype terms (1)
More specific conditions that are subtypes of Tuberculosis, Multidrug-Resistant in the MeSH hierarchy.
- Extensively Drug-Resistant Tuberculosis
15 drugs (13 approved, 2 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (8)
Phase 3 trials (12)
Phase 2 trials (11)
Phase 1 trials (7)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (60)
- Pfizer
- Novartis
- IUATLD, Inc
- Scientific Center for Anti-infectious Drugs, Kazakhstan
- Epicentre
- Otsuka
- Global Alliance for TB Drug Development
- National Institutes of Health (NIH)
- Medical Research Council
- National Institute of Allergy and Infectious Diseases (NIAID)
- World Health Organization
- Boston University
- University of London
- Harvard University
- GSVM Medical College
- Institute of Tropical Medicine, Belgium
- Johns Hopkins University
- Nanjing Medical University
- Partners in Health
- University of Limpopo
- University of Liverpool
- University of Nebraska
- University of Sussex
- Fudan University
- University of California, San Francisco
- University of Cape Town
- University of Basel
- Department of Defense
- Aurum Institute
- University of the Witwatersrand
- +30 more
Organization Involved with Phase 2 Indications (18)
- Archivel Farma S.L.
- Dankook University
- Seoul National University
- Yale University
- Yonsei University
- Columbia University
- University of Ulsan
- Badalona Hospital Germans Trias i Pujol
- Government of Korea
- Catholic University of Korea
- University of Kwa-Zulu Natal
- University of Texas, San Antonio
- Korean Institute of Tuberculosis
- Macleods Pharmaceuticals, Ltd
- Sungkyunkwan University
- Centers for Disease Control and Prevention (CDC)
- Pusan National University
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (1)